Trial Profile
Phase I/II Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 11 Feb 2024
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary) ; Pembrolizumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 02 Feb 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2025.
- 01 Aug 2022 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 01 Aug 2022 Planned primary completion date changed from 30 Jun 2022 to 30 Jun 2023.